Skip to content

13F-HR filed by ACUTA CAPITAL PARTNERS, LLC

ACUTA CAPITAL PARTNERS, LLC filed this 13F-HR for the quarter ended 2018-09-30, filed 2018-11-07, with 31 holding rows worth $280,350,000.

Accession
0001493152-18-015288
Filed
2018-11-07
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2018

A holdings report, 31 entries on the cover page, a total value of $280,350,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $280,350,000 with VALUE read as thousands by filing date, 13F file number 028-16527. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
IMMUNOMEDICS INC452907108COM2,055,500$42,816,000thousands by filing date
ASSEMBLY BIOSCIENCES INC045396108COM930,000$34,540,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM2,222,701$25,005,000thousands by filing date
KADMON HLDGS INC48283N106COM7,395,000$24,699,000thousands by filing date
CHEMBIO DIAGNOSTICS163572209COM2,030,533$21,321,000thousands by filing date
ARROWHEAD PHARMACEUTICALS IN04280A100COM775,000$14,857,000thousands by filing date
IRIDEX CORP462684101COM1,947,500$12,367,000thousands by filing date
CAS MED SYS INC124769209COM5,263,508$12,001,000thousands by filing date
VERACYTE INC COM92337F107Stock1,092,500$10,433,000thousands by filing date
SPDR SER TR78464A870S&P BIOTECH100,000$9,587,000thousands by filing dateput
REGENERON PHARMACEUTICALS COM75886F107Stock20,000$8,081,000thousands by filing dateput
ARGENX SE SPONSORED ADR04016X101ADR105,000$7,963,000thousands by filing date
MADRIGAL PHARMACEUTICALS INC COM558868105Stock33,000$7,066,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock482,500$6,369,000thousands by filing date
COHERUS ONCOLOGY INC19249H103COM353,500$5,833,000thousands by filing date
ASSEMBLY BIOSCIENCES INC045396108COM147,500$5,478,000thousands by filing datecall
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR71,500$5,066,000thousands by filing date
BIOHAVEN PHARMACEUTICAL HOLDING11196105COM132,500$4,975,000thousands by filing date
ARROWHEAD PHARMACEUTICALS IN04280A100COM200,000$3,834,000thousands by filing datecall
ACER THERAPEUTICS INC00444P108CMN109,270$3,370,000thousands by filing date
Viewra, Inc92672L107COM311,500$2,916,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM128,844$2,849,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock170,000$2,042,000thousands by filing date
BIOHAVEN PHARMACEUTICAL HOLDING11196105COM53,800$2,020,000thousands by filing datecall
ENDOCYTE INC29269A102COM92,000$1,634,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW71,000$1,155,000thousands by filing date
COHERUS ONCOLOGY INC19249H103COM50,000$825,000thousands by filing datecall
AMAG PHARMACEUTICALS INC00163U106COM40,000$800,000thousands by filing dateput
ALIMERA SCIENCES INC016259103COM267,500$262,000thousands by filing date
GTX INC DEL40052B207COM NEW100,000$157,000thousands by filing dateput
ONCOBIOLOGICS INC68235M105COM29,082$29,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001493152-18-015288this filing2018-11-07acceptance time not in the bulk data set